Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;30(6):2051-2061.
doi: 10.1007/s10787-022-01072-1. Epub 2022 Oct 22.

Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders

Heena Khan  1 , Chanchal Tiwari  1 , Amarjot Kaur Grewal  1 , Thakur Gurjeet Singh  2 , Simran Chauhan  1 , Gaber El-Saber Batiha  3
Affiliations
Review

Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders

Heena Khan et al. Inflammopharmacology. 2022 Dec.

Abstract

Neurodegenerative illness develops as a result of genetic defects that cause changes at numerous levels, including genomic products and biological processes. It entails the degradation of cyclic nucleotides, cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP). PDE7 modulates intracellular cAMP signalling, which is involved in numerous essential physiological and pathological processes. For the therapy of neurodegenerative illnesses, the normalization of cyclic nucleotide signalling through PDE inhibition remains intriguing. In this article, we shall examine the role of PDEs in neurodegenerative diseases. Alzheimer's disease, Multiple sclerosis, Huntington's disease, Parkinson's disease, Stroke, and Epilepsy are related to alterations in PDE7 expression in the brain. Earlier, animal models of neurological illnesses including Alzheimer's disease, Parkinson's disease, and multiple sclerosis have had significant results to PDE7 inhibitors, i.e., VP3.15; VP1.14. In addition, modulation of CAMP/CREB/GSK/PKA signalling pathways involving PDE7 in neurodegenerative diseases has been addressed. To understand the etiology, treatment options of these disorders mediated by PDE7 and its subtypes can be the focus of future research.

Keywords: Cyclic adenosine monophosphate; Neurodegenerative disease; PDE-7; Phosphodiesterases; cGMP.

PubMed Disclaimer

References

    1. Amin SA, Bhargava S, Adhikari N, Gayen S, Jha T (2018) Exploring pyrazolo [3, 4-d] pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques. J Biomol Struct Dyn 36(3):590–608. https://doi.org/10.1080/07391102.2017.1288659 - DOI - PubMed
    1. Bender AT, Beavo JA (2004) Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Neurochem Int 45(6):853–857. https://doi.org/10.1016/j.neuint.2004.03.015 - DOI - PubMed
    1. Blokland A, Menniti FS, Prickaerts J (2012) PDE inhibition and cognition enhancement. Expert Opin Ther Pat 22(4):349–354. https://doi.org/10.1517/13543776.2012.674514 - DOI - PubMed
    1. Bloom TJ, Beavo JA (1996) Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci 93(24):14188–14192. https://doi.org/10.1073/pnas.93.24.14188 - DOI - PubMed - PMC
    1. Bolger GB (2017) The PDE4 cAMP-specific phosphodiesterases: targets for drugs with antidepressant and memory-enhancing action. In: Phosphodiesterases: CNS functions and diseases, pp 63–102. https://doi.org/10.1016/S0065-7743(07)42001-2

MeSH terms

LinkOut - more resources